West Pharmaceutical
729 hedge funds and large institutions have $32.2B invested in West Pharmaceutical in 2021 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 277 increasing their positions, 226 reducing their positions, and 63 closing their positions.
114% more first-time investments, than exits
New positions opened: 135 | Existing positions closed: 63
23% more repeat investments, than reductions
Existing positions increased: 277 | Existing positions reduced: 226
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
13% more capital invested
Capital invested by funds: $28.5B → $32.2B (+$3.68B)
9% more funds holding
Funds holding: 670 → 729 (+59)
1.97% more ownership
Funds ownership: 91.11% → 93.09% (+2%)
30% less call options, than puts
Call options by funds: $63.3M | Put options by funds: $90.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$496M |
| 2 |
BlackRock
New York
|
+$286M |
| 3 |
Janus Henderson Group
London,
|
+$113M |
| 4 |
Morgan Stanley
New York
|
+$67.4M |
| 5 |
Man Group
London,
United Kingdom
|
+$56.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$117M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$107M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$75.3M |
| 4 |
Neuberger Berman Group
New York
|
-$56.6M |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$56.3M |
WST Hedge Fund Activity: Q4 2021 in Review
729 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q4 2021, worth a combined $32.2B — up 13% from $28.5B a quarter earlier.
Buyers outnumbered sellers: 135 funds opened new WST positions and 63 closed out — a net gain of 72 holders — while 277 added to existing stakes and 226 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $496M. The largest seller was Victory Capital Management, cutting an estimated $117M.
- 729 institutional investors held West Pharmaceutical (WST) as of Q4 2021, up from 670 in Q3 2021.
- Funds reported $32.2B of West Pharmaceutical stock for Q4 2021, up 13% quarter-over-quarter.
- 135 funds opened new West Pharmaceutical positions in Q4 2021 and 63 closed out, a net change of +72 holders.
- The largest West Pharmaceutical buyer in Q4 2021 was T. Rowe Price Associates, an estimated $496M added.
- The largest West Pharmaceutical seller in Q4 2021 was Victory Capital Management, an estimated $117M sold.
Based on aggregated 13F filings for Q4 2021.